Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 7/20 | 0.76 |
| ▸ | BRS3 | P32247 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23419718 | 0.92 | MARS2 (0.77) | MARS2BRS3P2RX7ADORA3MAPT | |
| SCHEMBL23419627 | 0.89 | MARS2 (0.74) | MARS2 | |
| SCHEMBL23419420 | 0.88 | MARS2 (0.66) | MARS2BRS3P2RX7ADORA3MAPT | |
| SCHEMBL20596125 | 0.86 | MARS2 (1.00) | MARS2BRS3P2RX7MAPTOPRM1 | |
| SCHEMBL23419474 | 0.82 | MARS2 (0.65) | MARS2 | |
| SCHEMBL23419421 | 0.82 | MARS2 (0.52) | MARS2BRS3ADORA3MAPTS1PR1 | |
| SCHEMBL23419412 | 0.82 | MARS2 (0.53) | MARS2P2RX7 | |
| SCHEMBL23419297 | 0.81 | MARS2 (0.65) | MARS2P2RX7 | |
| SCHEMBL23419308 | 0.81 | MARS2 (0.65) | MARS2 | |
| SCHEMBL23419650 | 0.81 | MARS2 (0.51) | MARS2BRS3P2RX7ADORA3S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885BRS3 4505/4885P2RX7 4283/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885BRS3 4478/4885P2RX7 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.